IVERIC bio, Inc.
DelistedCIK 1410939fmd_1MR9SG42SFCQHE5DX6MD8RZ5JMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 05, 2007 to Mar 31, 2023, 51 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 51 | 210 | 0 | 0 | – | – | – |
| Research and development | 33 | 88 | 131 | 196 | 66 | 42 | 40 | 63 | 85 | 117 |
| Total operating expenses | 47 | 122 | 175 | 246 | 102 | 65 | 61 | 89 | 115 | 190 |
| Operating income | (47) | (81) | (124) | (196) | 108 | (65) | (61) | (89) | (115) | (190) |
| Other non-operating income (expense) | (1) | 0 | 0 | 0 | (0) | (0) | 0 | (0) | (0) | 0 |
| Income before taxes | (51) | (80) | (123) | (194) | 109 | 62 | (59) | (88) | (115) | (185) |
| Income tax expense | – | 36 | (17) | (0) | (5) | (1) | (0) | (4) | 0 | 0 |
| Net income from continuing operations | – | (117) | (106) | (193) | 114 | 63 | (59) | (85) | (115) | (185) |
| Net income | (51) | (117) | (106) | (193) | 114 | 63 | (59) | (85) | (115) | (185) |
| Net income to common shareholders | (57) | (117) | (106) | – | – | – | – | – | – | – |